乐卡地平是一种亲脂性第三代二氢吡啶-钙通道阻滞剂（DHP-CCB）。
| Cas No. | 100427-26-7 |
| 别名 | 乐卡地平 |
| 化学名 | 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| Canonical SMILES | CC(N1)=C(C(OC)=O)C(C(C(OC(C)(CN(CCC(C2=CC=CC=C2)C3=CC=CC=C3)C)C)=O)=C1C)C4=CC(N(=O)=O)=CC=C4 |
| 分子式 | C36H41N3O6 |
| 分子量 | 611.73 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Lercanidipine is a calcium channel blocker of the dihydropyridine class.Target: Calcium ChannelLercanidipine is a calcium channel blocker of the dihydropyridine class, which works by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. Lercanidipine was effective and well-tolerated in patients with mild-to-moderate hypertension in the daily practice. The effectiveness and safety of the drug were independent of the degree of cardiovascular risk [1, 2]. References:
[1]. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70.
[2]. Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7. |
